Olysio (simeprevir) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	ИBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESCRIFOLLOWING LINK: PRIMETHERAPEUTICS.COM/		OSURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
□ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):			

Prime

Continued on next page.

Olysio (simeprevir) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🔲 NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
 □ Chronic hepatitis C virus (HCV) infection □ Other diagnosis: 3. REQUIRED CLINICAL INFORMATION 	ICD-10: : PLEASE PROVIDE ALL RELEVANT CLINIC		
PRIOR AUTHORIZATION. Clinical Information:			
	hronic hepatitis C genotype 1 or 4 infec	tion?* □ Yes □ No	
Does the patient have compensated li	iver disease? Yes No		
Will Olysio be used as monotherapy?	□ Yes □ No		
Does the patient have a documented *Must provide documentation.	baseline (pre-treatment) HCV RNA level	?* □ Yes □ No	
Does the patient have the NS3 Q80K p	oolymorphism?* Yes No *Must pro	ovide documentation.	
Is the patient undergoing a retreatme *Please provide previous therapy chair	nt of their disease?* □ Yes □ No rt notes showing dates of initial treatme	ent and response (include lab reports).	
Are there any other comments, diagnophysician feels is important to this rev	oses, symptoms, medications tried or fa view?	iled, and/or any other information the	
Please note: Not all drugs/diagnosis ar information is received.	e covered on all plans. This request may	be denied unless all required	
the Health Plan, insurer, Medical Grou	n provided is true and accurate to the be p or its designees may perform a routine curacy of the information reported on th	audit and request the medical	
Prescriber Signature or Electronic I.D.	Verification:	Date:	
	ompanying this transmission contain confidential eby notified that any disclosure, copying, distribu		

FAX THIS FORM TO: 800-424-7640

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

MAIL REQUESTS TO: Prime Therapeutics Management LLC

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.